sponsored
PatientsVille.com Logo

PatientsVille

Lpam Medical Research Studies

Up-to-date List of Lpam Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lpam Medical Research Studies

Rank Status Study
1 Recruiting Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib
Outcome Measures: To compare the progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib.;   To compare the response rate, overall survival and toxicity of high-dose melphalan versus high-dose melphalan and bortezomib
2 Recruiting Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
Outcome Measures: Maximum Tolerated Dose (MTD) of Pomalidomide with Melphalan and Dexamethasone (PMD).;   Complete Response (CR) Rate
3 Recruiting Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Conditions: Central Nervous System Embryonal Tumor;   Germ Cell Tumors
Interventions: Drug: Melphalan;   Drug: Carboplatin;   Drug: Sodium thiosulfate;   Drug: Filgrastim;   Drug: Pegfilgrastim
Outcome Measures: PHASE I: PRIMARY OBJECTIVE To determine the maximum tolerated dose (MTD) of IA melphalan given with IA carboplatin, osmotic BBBD and delayed IV STS in subjects with recurrent or progressive embryonal and germ cell tumors of the CNS.;   PHASE II: PRIMARY OBJECTIVE To estimate the response rate in subjects with recurrent or progressive CNS embryonal and germ cell tumors treated with IA carboplatin, IA melphalan, osmotic BBBD and delayed IV STS.;   To describe 2-year progression-free survival (PFS) and overall survival (OS) rates in subjects with recurrent or progressive CNS embryonal and germ cell tumors treated with IA carboplatin, IA melphalan, osmotic BBBD and delayed IV STS.;   To describe neuropsychological and audiology outcomes in subjects with recurrent or progressive CNS embryonal and germ cell tumors treated with IA carboplatin, IA melphalan, osmotic BBBD and delayed IV STS;   To describe the overall toxicity of IA carboplatin and IA melphalan in conjunction with osmotic BBBD and delayed STS chemoprotection in subjects with recurrent or progressive CNS embryonal or germ cell tumors.
4 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: Maximum tolerated dose of bortezomib as defined as the highest dose tested in which none or only one patient experiences dose limiting toxicity attributable to the study regimen;   Feasibility of escalating doses of bortezomib with or without TMI in combination with FLU and MEL as preparative regimen for allogeneic hematopoietic stem cell transplant in patients with high risk multiple myeloma;   Frequency of clinical response (i.e., complete, partial, or very good partial response);   Frequency of primary and secondary engraftment failure;   Time to neutrophil and platelet engraftment;   Progression-free survival;   Incidence of acute and chronic graft-versus-host disease;   Overall survival;   Minimal residue disease
5 Recruiting Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
Condition: Regional Melanoma
Interventions: Drug: Melphalan;   Drug: Tropisetron;   Drug: Morphine
Outcome Measures: Tumor response;   progression free survival;   survival rate;   time to progression;   number of adverse events;   Quality of life
6 Not yet recruiting XM02 Filgrastim to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
Condition: Multiple Myeloma
Interventions: Drug: XM02 filgrastim and high dose melphalan;   Drug: High dose melphalan;   Procedure: Autologous Stem Cell Transplant
Outcome Measures: CR and sCR;   Toxicity of XM-02 filgrastim + (High Dose Melphalan) HDM to HDM alone;   Overall Response Rate (CR+ sCR) + VGPR + PR;   Overall survival comparing XOM filgrastim + HDM to HDM alone;   Progression-free survival comparing XOM filgrastim + HDM to HDM alone;   Neutrophil engraftment comparing XOM filgrastim + HDM to HDM alone;   Platelet engraftment comparing XOM filgrastim + HDM to HDM alone
7 Recruiting Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Previously Treated Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Drug: tacrolimus;   Drug: sirolimus
Outcome Measures: Progression-free survival;   Overall survival;   Cumulative incidence of relapse/progression;   Cumulative incidence of non-relapse mortality defined as death occurring in a patient from causes other than relapse or progression;   Overall toxicity graded using the Bearman scale and CTCAE v4.0;   Incidence and severity of acute GVHD of grades 2-4 and 3-4 according to the consensus grading;   Incidence and severity of chronic GVHD scored according to National Institute of Health (NIH) consensus staging;   Microbiologically documented infection
8 Recruiting Microdose Study of Melphalan, Bortezomib and Dexamethasone
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib;   Drug: Dexamethasone
Outcome Measure: Change from baseline in gene expression at 15, 30, 60, 120 minutes upon microdose drug exposure.
9 Unknown  Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Melphalan
Outcome Measures: To determine the safety and toxicity of the bendamustine/melphalan regimen;   To determine the maximally tolerated dose of bendamustine in combination with melphalan as an autologous regimen based on dose limiting toxicities.;   Survival, overall and progression free
10 Recruiting Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
Condition: Multiple Myeloma
Interventions: Drug: Busulfan;   Drug: Melphalan;   Drug: Lenalidomide
Outcome Measures: • Minimal Residual Disease (MRD) negativity at day 100 post ASCT;   • To determine the pattern, positivity (in terms of percentages) or negativity of MRD analysis during lenalidomide maintenance.;   • To determine the response rate using conventional immunoglobulin and monoclonal protein-based markers at day 100 post ASCT and best response using lenalidomide maintenance.;   • To determine the effectiveness of using the HevyLite Chain assay to assess anti-tumour response at day 100 post ASCT and during lenalidomide maintenance;   • To determine the toxicity of busulfan and melphalan when used as a high-dose conditioning therapy for ASCT.;   • To determine the toxicity of lenalidomide maintenance post busulfan and melphalan conditioning ASCT.;   • To determine the progression free survival (PFS) and overall survival (OS) of this program.
11 Recruiting Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (phase I);   The number and severity of all adverse events (phase I);   Proportion of complete responses (CR) defined as a CR noted as the objective status on two consecutive evaluations (phase II);   CR rate at day 100 estimated by the total number of patients who achieve a complete CR by day 100 post-transplant divided by the total number of evaluable patients;   Time to progression;   Maximum grade for each type of adverse event
12 Recruiting Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
Outcome Measures: Progression-Free Survival;   Overall Survival (OS);   Complete Response (CR) rate;   Overall Response Rate (ORR);   Change from baseline in health-related quality of life (HR-QOL) score
13 Recruiting Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Auto Stem Cell Transplant
Intervention: Drug: Bortezomib
Outcome Measures: To determine the progression-free survival of patients with multiple myeloma treated with tandem cycles of high-dose melphalan followed by high-dose melphalan in combination with bortezomib with autologous HSC transplantation.;   To determine the response rate, overall survival, and regimen-related toxicities of patients with multiple myeloma treated with high-dose melphalan or high-dose melphalan in combination with bortezomib given in tandem transplants.
14 Recruiting Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib, Melphalan, Prednisone (VMP);   Drug: 1 or 2 cycle(s) HDM (High Dose Melphalan);   Drug: 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
Outcome Measures: For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).;   For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first;   For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first;   Overall survival measured from the time of registration /randomization R1/ randomization R2. Patients still alive or lost to follow up are censored at the date they were last known to be alive.;   Toxicity;   Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment.
15 Recruiting Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Condition: Multiple Myeloma
Intervention: Drug: busulfan, melphalan and fludarabine
Outcome Measures: To determine the rates of progression-free (PFS) and of overall survival (OS);   To assess the transplant-related morbidity and mortality for patients with multiple myeloma.;   To assess the incidence of and severity of acute and chronic GvHD;   To compute the current multiple myeloma free survival curve in order to account for patients who relapse and are restored to remission through DLI.;   To explore the associations between progression free survival and the CT antigens -CT7, CT10, MAGE-A3 and NY-ESO-1.
16 Recruiting Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Outcome Measure: transplant related mortality (TRM) for patients undergoing RIT with co-morbidities or who are otherwise not eligible or unable to receive a myeloablative allogeneic HSCT
17 Recruiting Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Condition: Autoimmune Disorder
Interventions: Biological: anti-thymocyte globulin;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: prednisone;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
Outcome Measures: Incidence of grades 4-5 regimen-related toxicity as assessed by the Regimen Related Toxicity Scale;   Transplant-related mortality;   Disease responses as assessed by clinical, laboratory and radiologic evaluation;   Engraftment kinetics;   Efficacy of peripheral blood stem cell mobilization from syngeneic donors and autograft recipients
18 Recruiting A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).
Condition: Castrate Resistant Prostate Cancer
Interventions: Drug: Melphalan;   Drug: Lenograstim
Outcome Measures: To determine the efficacy of intensified intravenous Melphalan with autologous whole blood stem cell transplantation in patients with castration resistant prostate cancer using progression free survival.;   To determine weather early falls (two weeks)in circulating tumor cells (CTC)predict the progression free survival;   To assess the changes in prostate specific antigen pre and post treament;   To study progression free survival and overall survival;   To assess the effect of this schedule in reintroduction of hormone senstivity;   To study the Quality of life.
19 Recruiting High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Condition: Lymphoma
Interventions: Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplantation;   Drug: Palifermin
Outcome Measure: Event-Free Survival (EFS)
20 Unknown  Intravitreal Injections of Melphalan for Retinoblastoma
Condition: Retinoblastoma
Intervention: Drug: IVit Melphalan
Outcome Measures: treatment response;   complications

These studies may lead to new treatments and are adding insight into Lpam etiology and treatment.

A major focus of Lpam research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Lpam